Class Settlement Tentatively Approved In Consumer MDL Over Generic Wellbutrin

A class settlement gained tentative court approval Feb. 1 in federal consumer fraud multidistrict litigation alleging that certain generic versions of the Wellbutrin antidepressant are less effective than the branded drug (In re Budeprion XL Marketing and Sales Practices Litigation, E.D. Pa., No. 09-2811).

Defendants Impax Laboratories Inc. and Teva Pharmaceuticals USA, who manufacture and market a Bupropion Hydrochloride XL product (BP XL), a generic formulation of the branded Wellbutrin XL, have agreed to certain injunctive relief under the settlement, according to the plaintiffs’ motion in support of preliminary approval.

The plaintiffs’ motion says the settlement calls for ...